A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)
NCT ID: NCT02913456
Last Updated: 2024-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
629 participants
OBSERVATIONAL
2016-11-16
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
NCT02595762
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
NCT02611310
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer
NCT04191382
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
NCT02980341
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
NCT05155566
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HER2-positive unresectable LA/mBC
Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie
Graz, , Austria
LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
Graz, , Austria
Klinikum Klagenfurt; Abt. f. Hämatologie u. internistische Onkologie
Klagenfurt, , Austria
LKH Hochsteiermark; Abt. für Hämato-Onkologie
Leoben, , Austria
Ordensklinikum Linz Elisabethinen ; I. INTERNE ABT.
Linz, , Austria
A.Ö. Krankenhaus Der Barmherzigen Schwestern Ried; Interne Abtl.
Ried-innkreis, , Austria
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
Vienna, , Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
Vienna, , Austria
Hanusch-Krankenhaus; Geburtshilfliche und Gynäkologische Abteilung
Vienna, , Austria
A.Ö. Lhk Villach; Abt. Für Gynäkologie
Villach, , Austria
Landesklinikum Wiener Neustadt; Innere Medizin, Hämatologie u. internistische Onkologie
Wiener Neustadt, , Austria
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
Plovdiv, , Bulgaria
Complex Oncological Center - Plovdiv, EOOD
Plovdiv, , Bulgaria
Mdozs - Russe
Rousse, , Bulgaria
MHAT Nadezhda
Sofia, , Bulgaria
Tokuda Hospital; Medical Oncology Department
Sofia, , Bulgaria
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
Sofia, , Bulgaria
SHATOD - Sofia
Sofia, , Bulgaria
Complex Oncology Center-Burgas; Medical Oncology
Sofia, , Bulgaria
District Oncology Dispensary; Dept of Chimiotherapy
Stara Zagora, , Bulgaria
District Oncology Dispensary Wit Stationary
Varna, , Bulgaria
Comprehensive Oncology Center - Vratsa
Vratsa, , Bulgaria
Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
Bari, Apulia, Italy
Ospedale Barletta - Mons. Dimiccoli; Dip. Oncologia
Barletta, Apulia, Italy
A.O. Universitaria Policlinico Di Modena; Oncologia
Modena, Emilia-Romagna, Italy
RCCS - Centro di Riferimento; Oncologia Medica B
Aviano (PN), Friuli Venezia Giulia, Italy
Ospedale S. Maria Goretti; Divisione Di Oncologia Medica
Latina, Lazio, Italy
Ospedale S.S. Trinità Nuovo; Divisione Oncologia
Sora, Lazio, Italy
Ospedale Belcolle Di Viterbo; Oncologia
Viterbo, Lazio, Italy
Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina
Brescia, Lombardy, Italy
Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica
Ponderano (BI), Piedmont, Italy
Ospedale Cannizzaro, Oncologia
Catania, Sicily, Italy
Casa Di Cura Di Alta Specialita La Maddalena; Dept. Oncologico Di Iii Livello
Palermo, Sicily, Italy
A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica
Ancona, The Marches, Italy
Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia
Florence, Tuscany, Italy
Ospedale San Luca; Oncologia
Lucca, Tuscany, Italy
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
Sant'Andrea Delle Fratte (PG), Umbria, Italy
Ospedale Civile; Oncologia Medica
Camposampiero, Veneto, Italy
Azienda Ospedaliero Universitaria di Ferrara - U.O. Di Oncologia
Cona (FE), Veneto, Italy
Azienda ULSS 21 Ospedale Mater Salutis; Dip. di Oncologia
Legnago (VR), Veneto, Italy
A.O.U. Integrata Verona - Policlinico G.B. Rossi; Oncologia Medica - Dip. di Medicina
Verona, Veneto, Italy
Hospital Garcia de Orta; Servico de Oncologia Medica
Almada, , Portugal
IPO de Coimbra; Servico de Oncologia Medica
Coimbra, , Portugal
Hospital Santo Antonio dos Capuchos;Servico de Oncologia Medica
Lisbon, , Portugal
Hospital de Santa Maria; Servico de Oncologia Medica
Lisbon, , Portugal
Hospital Beatriz Angelo; Departamento de Oncologia
Loures, , Portugal
IPO do Porto; Servico de Oncologia Medica
Porto, , Portugal
County Hospital Alba; Oncology
Alba Iulia, , Romania
"Filantropia" Clinical Hospital; Gynecological Oncology
Bucharest, , Romania
Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti
Bucharest, , Romania
Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology
Cluj-Napoca, , Romania
Prof. Dr. I. Chiricuta Institute of Oncology
Cluj-Napoca, , Romania
Centrul de Oncologie Sfantul Nectarie
Craiova, , Romania
Oncomed SRL
Timișoara, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MO39146
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.